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As marijuana policy reform in the U.S. has evolved over the past 
twenty years, one proposal keeps gaining attention: drug rescheduling.1  
State officials, members of Congress, the media, scholars, and the 
advocacy community have—to varying degrees—held up rescheduling as 
a solution to some of the challenges current federal law imposes on 
marijuana policy.  Despite the near-celebrity status of rescheduling as a 
reform, it is among the most misunderstood proposals—both in terms of 
the process and its consequences. 
This article seeks to clarify this conversation.  Section I will 
describe precisely how rescheduling works, through legislative and 
administrative processes.  The section will go on to detail the history of 
marijuana rescheduling in the U.S., including formal rescheduling 
petitions filed with the U.S. and some of the legislative proposals to do 
the same.  Section II will detail both the consequences and limits of 
marijuana rescheduling.  Section III will describe some alternative, 
additional proposals that could have more meaningful impacts on 
marijuana policy.  Section IV will briefly conclude. 
 
I. HOW RESCHEDULING WORKS 
 
The Controlled Substances Act [CSA] designates different “schedules” for 
substances the federal government seeks to regulate.  The federal government 
designates a schedule for each substance based on its medical value, abuse 
potential, and safety.  The highest level of control—Schedule I—is reserved for 
substances the government determines have “a high potential for abuse . . . no 
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currently accepted medical use in treatment in the United States . . . [and] a lack of 
accepted safety for use.” 
Schedule I substances include marijuana, heroin, LSD, MDMA, GHB, 
ecstasy, bath salts, and Quaaludes, among others.  By comparison, Schedule II—a 
government designation of a substance having some medical value—includes 
cocaine, methamphetamines, OxyContin, morphine, and opium. 
Reform advocates argue that marijuana should be placed on a different 
schedule that better reflects the medical, safety, chemical, and pharmacological 
realities of the substance.  In fact, as we have argued elsewhere, marijuana’s 
Schedule I status “creates a circular policy trap . . . .  Research on the medical 
value of cannabis is limited by the Schedule I designation of cannabis, which 
asserts that the substance has no medicinal value.”2  The process of moving a 
substance from one schedule to another is commonly known as rescheduling.3   
Efforts to reschedule marijuana are not new.  There have been multiple calls 
for Congress to amend the CSA with regard to marijuana.  Although some 
marijuana advocates have argued that the President can reschedule marijuana with 
a stroke of the pen—by executive action, however, he cannot.  Instead, marijuana 
rescheduling via administrative process is a long, complex, multi-agency process.  
We will describe legislative and administrative rescheduling processes in turn. 
 
A. Legislative Rescheduling 
 
Congressional rescheduling of a drug is a straightforward process.  Congress 
can amend the CSA to move cannabis to Schedule II (or to another schedule, or off 
the schedules entirely [“descheduling”]).4  Over the years, many bills have been 
introduced that would either reschedule or deschedule marijuana.  Each proposal 
has died in committee.5  Elected officials perceive the politics of marijuana policy 
                                                                                                                            
 
2   Id. at 8.  
3   Rescheduling is used in rulemaking by the DEA to mean the transfer of a substance from 
one schedule to another.  See Schedules of Controlled Substances: Rescheduling of Buprenorphine 
from Schedule V to Schedule III, 21 C.F.R. § 1308 (2016). 
4   John Hudak & Grace Wallack, How to Reschedule Marijuana, and Why It’s Unlikely 
Anytime Soon, BROOKINGS INST.: FIXGOV (Feb. 13, 2015), 
https://www.brookings.edu/blog/fixgov/2015/02/13/how-to-reschedule-marijuana-and-why-its-
unlikely-anytime-soon/.   
5   In 1975, Rep. Edward Koch introduced the Marihuana Control Act, H.R. 8984, 94th Cong. 
(1975), which was referred to committee with no further action.  In 1979, Morris K. Udall repeatedly 
introduced H.R. 3950, 96th Cong. (1979) to decriminalize marijuana, also with no further action.  In 
1985, Rep. Stewart McKinney introduced H.R. 2232, 99th Cong. (1985), a bill to amend the CSA to 
provide for the therapeutic uses of marihuana, which would move the substance to Schedule II.  This 
bill was also referred to committee with no further action.  The bill was reintroduced in 1995, also to 
no further action.  More recently, Rep. Barney Frank introduced the Ending Federal Marijuana 
Prohibition Act of 2011, H.R. 2306, 112th Cong. (2011), which was referred to committee with no 
further action.  Rep. Jared Polis introduced a similar bill in 2013, the Ending Federal Marijuana 




to be toxic, despite polls of Americans that show robust support for marijuana 
reform—particularly around medical marijuana.6  Once Congress catches up with 
public opinion, it could pass an amendment to the CSA, and a presidential 
signature would reschedule marijuana. 
 
B. Administrative Rescheduling 
 
Rescheduling is not a simple process for the executive branch.7  A petition, 
initiated from an outside party or from within the administration, must be reviewed 
first by the Department of Health and Human Services [HHS] (via the Food and 
Drug Administration [FDA]) and the Attorney General, who typically delegates 
that task to the Drug Enforcement Administration [DEA].  Together, each agency 
reviews the petition according to eight key factors to determine if there is a 
scientifically accepted medical use for the drug, its potential for and history of 
abuse, and any risk to the public health.8  DEA and HHS make recommendations 
to the Attorney General with regard to the proper scheduling of the substance.  The 
Attorney General then makes a determination about proper scheduling.  If the 
Attorney General finds the substance is properly scheduled, the process stops and 
the status quo remains.  If the Attorney General determines a change in scheduling 
is founded, she initiates the rulemaking process, consistent with the CSA and the 
Administrative Procedure Act. 
 
C. The History of Rescheduling Proposals 
 
Formal Congressional efforts to reschedule marijuana began in 1981 when 
Congressman Stewart McKinney (R-CT) introduced House Bill 4498, “a bill to 
provide for the therapeutic use of marijuana in situations involving life-threatening 
illnesses and to provide adequate supplies of marijuana for such use.”  The bill 
would have endorsed marijuana supply expansion and access.  It also sought to 
move marijuana to Schedule II.  This bill garnered eighty-four cosponsors, 
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including conservatives like future House Speaker Newt Gingrich, and liberals like 
Michigan’s John Conyers and California’s George Miller.9  
Additional rescheduling proposals sprung up in Congress over the years, 
including an effort by Ron Paul and Barney Frank in 2011.  The latest efforts 
include the comprehensive CARERS Act—the first proposal originating in the US 
Senate—and a recent bill by Sen. Bernie Sanders (I-VT) to deschedule marijuana. 
Administrative efforts have spanned decades as well.  Four petitions have 
been initiated to reschedule marijuana or remove it from the schedules entirely 
since 1972.  Each has been denied or stalled by DEA with disposition times 
ranging from five to more than twenty years.10  The first petition, initiated by the 
National Organization for the Reform of Marijuana Laws (NORML) in 1972, was 
not acted upon by DEA until 1986, after three different federal court rulings 
required DEA to review the petition.11  It was ultimately denied in 1994, twenty-
two years after its submission.  The second petition was initiated in 1995 and 
denied in 2001, and the third, submitted in 2002, was denied in 2011, despite the 
multitude of states with medical marijuana programs by that time.12  The most 
recent petition (submitted by then-Governors Christine Gregoire (WA) and 
Lincoln Chaffee (RI) in 2011) is still under review.13 
In general, moving a drug between schedules has been an uncommon 
occurrence since the CSA was passed in 1970.  Some noteworthy cases of 
rescheduling include Marinol (now Schedule III) and Hydrocodone Combination 
Products (HPCs), which are now Schedule II.  Marinol—the trade name for the 
synthetic cannabinoid, dronabinol—was first moved from Schedule I to II in 1986, 
and then from II to III in 1999.14   
 
II. CONSEQUENCES AND LIMITS OF MARIJUANA RESCHEDULING 
 
A. What Would Rescheduling Do? 
 
The distinction between Schedule I and Schedule II centers on whether a 
substance has medical value.  Schedule I drugs have “no currently accepted 
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medical use in treatment in the United States” while Schedule II drugs have 
“currently accepted medical use in treatment in the United States or . . . with severe 
restrictions.”15  Substances under both schedules I and II are believed to have “high 
potential for abuse.”  Rescheduling marijuana—with the government 
acknowledgement of its medical value—would have the most direct effects on the 
perception of marijuana, both in the government and for the public, which could 
have secondary policy effects. 
The biggest policy impact of rescheduling marijuana from Schedule I to 
Schedule II, III, IV or V would be in the area of medical research, particularly with 
regard to researcher certification and licensure.  The precise schedule matters, but 
regardless, the policy effects of rescheduling would be limited.  
Researchers hoping to conduct research with Schedule I drugs undergo a 
multi-agency review and registration process.  First, researchers must submit the 
FDA’s Investigational New Drug (IND) application, and NIH-funded projects also 
undergo an additional, three-step NIH review.  Researchers then obtain a DEA 
registration for possessing the substance for research.  Researchers then submit 
their proposal and request for study drugs to the National Institute on Drug Abuse 
(NIDA) for review and to approve the supply of the drugs they need.16   For 
marijuana, unlike all other Schedule I drugs, there is a single production facility 
licensed by the DEA to produce research grade material—a farm at the University 
of Mississippi—which is overseen by NIDA.17  Both the DEA-mandated NIDA 
monopoly on research marijuana and DEA registration represent hurdles to 
research that would not be present if marijuana were a Schedule II drug.18 
Under DEA’s licensing system, there are categories of activities for which a 
medical professional must register in order to work with any scheduled drug (I– 
V). 19   For example, there are independent registrations for manufacturing, 
distribution, and research.  Research into substances in Schedule II–V requires a 
license for “[d]ispensing or [i]nstructing,” which is available for hospitals, 
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reschedules.  State rescheduling proceeds unless a challenge is filed.  See Uniform Controlled 
Substances Act § 201(f).  




pharmacies, practitioners, etc. 20   This is commonly called the “practitioner” 
registration, and covers the entire medical practice, not just an individual trial, and 
can be renewed every three years.  
Clinical trials with any Schedule I substance, however, always require a 
separate researcher registration, and is subject to more stringent controls and 
reporting requirements than any licensure required for research into non-Schedule I 
substances.  Thus, rescheduling marijuana from I to II (or another schedule) would 
remove a significant barrier to research in the form of more relaxed registration 
requirements for practitioners.21 
 
B. What Rescheduling Would Not Do 
 
Contrary to common misconceptions, reclassifying cannabis from Schedule I 
to Schedule II would not open the floodgates of dramatic change.  Unless 
descheduled marijuana would still be treated as a medicine, maintaining the legal 
limbo for states with recreational and medical marijuana programs (because state-
level medical marijuana is still not FDA approved).  Pharmaceuticals produced 
from scheduled substances still require FDA approval—a long, circuitous, and 
expensive path that cannabis products would be free to navigate once Schedule I 
prohibitions are removed. 
Rescheduling would not immediately remove the NIDA monopoly—a 
significant barrier, separate from Schedule I status, that hinders the integrity and 
conduct by research.22  Removing the NIDA monopoly would require an additional 
step, either by Congress or the DEA.  The DEA still maintains production quotas 
for Schedules I and II, and licenses producers for all scheduled drugs.  So, 
rescheduling would not immediately impact the available supply of marijuana 
available for research.  
As we will detail below, rescheduling marijuana to Schedule III, IV, or V 
could have tax relief implications sought out by the cannabis industry and minor 
benefits for criminal justice advocates, but only under additional, specific 
circumstances.  Only removal from the CSA’s schedules entirely would facilitate 
full legalization in the U.S.  At present, this option is politically unlikely.  If it did 
                                                                                                                            
 
20  Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances, 21 
C.F.R. § 1301.13 (2014). 
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occur, it would likely come with separate, robust regulatory restrictions, just as 
legalizing states have implemented.23  
 
C. Rescheduling, Taxes, and Banking 
 
Beyond licensure and registration for medical research, rescheduling could 
have effects on financial matters relevant to the cannabis industry.  Under section 
280E of the Internal Revenue Code, “[n]o deduction or credit shall be allowed . . . 
in carrying on any trade or business if such trade or business . . . consists of 
trafficking in controlled substances (within the meaning of schedule I and II of the 
Controlled Substances Act).”24  For some marijuana businesses, this increases their 
effective tax rate to 100% or higher.  Rescheduling marijuana to Schedule III 
would mean that marijuana enterprises would be eligible for the same federal tax 
deductions that traditional businesses are eligible for.  
Aside from 280E, the impact of rescheduling on financial matters related to 
marijuana is limited.  All banks, national or state-based, must comply with all 
federal laws in order to maintain their charter and federal deposit insurance and 
avoid criminal and civil sanctions.25  Providing services to marijuana businesses 
put banks in violation of federal anti-money laundering statutes, the Banking 
Secrecy Act (BSA), and federal regulations.26  The BSA requires banks to file 
suspicious activity reports (SARs) on any depositor whose behavior they suspect 
may violate federal law.  In practice, this means banks must file an SAR on all 
activity involving a marijuana-related business because all financial transactions 
from that business produce funds derived from federally-illegal activity. 27   In 
addition, anti-money laundering statues (18 U.S.C. sections 1956 and 1957) make 
clear that all financial and monetary transactions using proceeds from “specified 
unlawful activities” are considered money laundering.  Failure to comply with any 
                                                                                                                            
 
23  In addition, descheduling of marijuana would violate the United States’ obligations under 
the United Nations’ Single Convention on Narcotic Drugs.  See generally UNITED NATIONS, SINGLE 
CONVENTION ON NARCOTICS DRUGS (1961), https://www.unodc.org/pdf/convention_1961_en.pdf.  
24  26 U.S.C. § 280E (2012).  
25  The Bank Secrecy Act, 31 U.S.C. § 5322 (2012) (criminal penalties); 31 U.S.C. § 5321 
(2012) (civil sanctions); 12 C.F.R. § 326, 353 (2015) (FDIC regulations for the Bank Secrecy Act 
compliance); 31 C.F.R. § 536 (2015) (Treasury regulations for compliance).  
26  JAMES M. COLE, U.S. DEP’T OF JUSTICE, MEMORANDUM FOR ALL U.S. ATT’Y GUIDANCE 




27  Financial Crimes Enforcement Network (FinCEN) has issued guidance allowing banks who 
serve marijuana businesses that follow applicable state law to submit a more limited SAR, but this 
has had little effect on the industry.  See U.S. DEP’T OF THE TREASURY, BSA EXPECTATIONS 
REGARDING MARIJUANA-RELATED BUSINESSES (Feb. 14, 2014), 
https://www.fincen.gov/sites/default/files/shared/FIN-2014-G001.pdf.  




of these laws could form the basis of prosecution against a bank, even if the 
underlying activity (i.e., a marijuana business) is state-legal.  Because rescheduling 
marijuana would not automatically legalize marijuana for medical (or recreational) 
use, it would have virtually no impact on the status of banking services for 
marijuana enterprises. 
 
D. Rescheduling and Criminal Penalties 
 
While many states have passed recreational, medical, or decriminalization 
laws, the fear of federal prosecution for marijuana use still exists.  Under federal 
law, possession of small amounts of marijuana on first offense is punishable by 
prison time, and penalties escalate dramatically based on the amount, related 
criminal activities (sale, cultivation, etc.) and the number of offenses. 28  
Considering the widespread use of marijuana,29 it is no wonder many advocates 
point to mandatory sentences for marijuana offenses as a basis for criminal justice 
reform.  Unfortunately, marijuana rescheduling would do very little to solve this 
issue.  
Because rescheduling would not change the federal status of the marijuana 
grown, processed, and sold in state-legal enterprises, it would have very little 
impact on criminal penalties.  Generally, penalties for possessing drugs in lower 
schedules are less harsh than those in Schedule I or II.30  However, Section 841 of 
the Controlled Substances Act outlines minimum and maximum penalties for 
marijuana specifically, as enacted at various times in the 1980s.  It is unlikely that 
rescheduling would have any impact on these mandatory penalties, and therefore 
congressional action amending the CSA would be necessary to reduce them.  
 
III. COMPREHENSIVE CANNABIS REFORM 
 
Those interested in marijuana policy reform approach it from different 
perspectives or with different motivations.  Some consider criminal justice aspects 
to be crucial.  Others see reform through the lens of public health.31  Still others see 
                                                                                                                            
 
28   U.S. DRUG ENF’T ADMIN., FEDERAL TRAFFICKING PENALTIES FOR MARIJUANA, HASHISH & 
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in the previous month.  See NAT’L INST. ON DRUG ABUSE, NIH, DRUGFACTS: NATIONWIDE TRENDS 
(revised June 2015), http://www.drugabuse.gov/publications/drugfacts/nationwide-trends (last visited 
Oct. 18, 2016). 
30  See 21 U.S.C. § 841 (2012).  
31  One option raised by public health advocates is reopening the Compassionate 
Investigational New Drug Program (CIND).  Beginning in the 1970s, the program distributed 
marijuana to a limited number of people, mostly suffering from chronic conditions or end-of-life 




free market values and business interests as the core concerns.  Frankly, some 
people just like smoking pot.  For every one of these groups, rescheduling is not a 
complete fix. 
Beyond rescheduling, other policy changes are necessary to satisfy most 
reformers.  In large part, those changes must come from Congress, as they rest 
beyond the reach of unilateral executive power.  Reform possibilities are 
numerous. 
The removal of the DEA-mandated NIDA monopoly on the production of 
marijuana is essential for the expansion of medical research and availability of 
diverse product.  Removal of the NIDA monopoly could happen administratively 
or by an act of Congress and could also happen with or without rescheduling.32 
As mentioned previously, rescheduling marijuana to Schedule II would do 
little for the economic challenges that face cannabis enterprises.  Moving 
marijuana to Schedule III or lower would ease the tax burden on businesses under 
IRC section 280E, but full banking access would likely require additional 
congressional action.33   
One solution to the question of legal status would be for Congress to pass a 
marijuana-specific bill that essentially codifies the 2013 Cole Memos.34  Such 
legislation could, in effect, create a carve out for marijuana from the traditional 
restrictions placed upon controlled substances under CSA, so that entities could 
operate so long as they meet specific federal and/or state regulatory guidelines.  
That move could be viewed as the equivalent of descheduling marijuana in states 
that have legalized it, while providing the necessary political cover for elected 
officials who desire the effect of that outcome without hanging a green albatross 
around their necks. 
It is important to note that a commercial-oriented carve-out for marijuana still 
would not, in itself, solve criminal justice concerns—at least for those caught 
purchasing and possessing a controlled substance without proper authorization.  
An additional provision or standalone piece of legislation would be needed to 
reduce or eliminate criminal penalties.  
 
 
                                                                                                                            
maladies.  The program was closed to new applicants in 1992.  Reopening this program would be a 
severely restricted, but nevertheless meaningful reform for medical marijuana patients.  Because the 
program does not implicate scheduling, we do not discuss it at length in this paper.  
32  HUDAK & WALLACK, supra note 1, at 10.  See CARERS Act, S. 683, 114th Cong. (2015); 
Lyle E. Craker, Dep’t of Justice Docket No. 05-16 (Feb. 12, 2007) (opinion and recommended 
ruling). 
33  The Treasury has considered making regulatory changes to the BSA to remove or reduce 
reporting requirements for banks when their accounts implicate a suspicious activity.  This would 
ease some banks’ nervousness, but would not be a whole-scale reform.  AM. BANKERS ASSOC., 
FREQUENTLY ASKED QUESTIONS: MARIJUANA AND BANKING 1 (Feb. 2014), 
https://www.aba.com/Tools/Comm-Tools/Documents/ABAMarijuanaAndBankingFAQFeb2014.pdf. 
34  COLE, supra note 26.  






While rescheduling has been popular among advocates, the press, and some 
members of Congress, it offers—at best—limited hope for reform.  Such a move 
would not automatically bestow legal status on existing medical marijuana 
enterprises, and marijuana would still have to go through the lengthy process of 
FDA approval before being legally marketable.  For tax purposes, placing 
marijuana in Schedule III would be the biggest boom to business, but beyond that, 
rescheduling would have limited effects on criminal penalties, banking services, 
and state-level recreational programs.  The most notable effect of rescheduling 
would be to remove some research barriers for medical marijuana, but would lack 
the comprehensive effects many supports seek. 
